![]() | |
Clinical data | |
---|---|
Pronunciation | /ˌaɪvəˈkæftər/ EYE-və-KAF-tər |
Trade names | Kalydeco |
Other names | VX-770 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a612012 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 99% |
Metabolism | CYP3A |
Elimination half-life | 12 hrs (single dose) |
Excretion | 88% faeces |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.226.211 |
Chemical and physical data | |
Formula | C24H28N2O3 |
Molar mass | 392.499 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Ivacaftor is a medication used to treat cystic fibrosis in people with certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (primarily the G551D mutation), who account for 4–5% cases of cystic fibrosis.[5][6] It is also included in combination medications, lumacaftor/ivacaftor, tezacaftor/ivacaftor, and elexacaftor/tezacaftor/ivacaftor which are used to treat people with cystic fibrosis.[7][8][9]
Ivacaftor was developed by Vertex Pharmaceuticals in conjunction with the Cystic Fibrosis Foundation and is the first medication that treats the underlying cause rather than the symptoms of the disease. It was approved by the U.S. Food and Drug Administration (FDA) in January 2012. It is one of the most expensive drugs, costing over US$300,000 per year, which has led to criticism of the high cost. The combination drug lumacaftor/ivacaftor was approved by the FDA in July 2015.
Cystic fibrosis is caused by any one of several defects in the CFTR protein, which regulates fluid flow within cells and affects the components of sweat, digestive fluids, and mucus. One such defect is the G551D mutation, in which the amino acid glycine (G) in position 551 is replaced with aspartic acid (D). G551D is characterized by a dysfunctional CFTR protein on the cell surface. In the case of G551D, the protein is trafficked to the correct area, the epithelial cell surface, but once there the protein cannot transport chloride through the channel. Ivacaftor, a CFTR potentiator, improves the transport of chloride through the ion channel by binding to the channels directly to induce a non-conventional mode of gating which in turn increases the probability that the channel is open.[10][11][12]
Kalydeco label
was invoked but never defined (see the help page).Kalydeco EPAR
was invoked but never defined (see the help page).Orkambi Label
was invoked but never defined (see the help page).Symdeko label
was invoked but never defined (see the help page).Symkevi EPAR
was invoked but never defined (see the help page).